SciELO - Scientific Electronic Library Online

vol.31 issue3Desempeño del ecocardiograma estrés con fármacos como herramienta pronóstica en pacientes con enfermedad coronaria conocida o sospechada author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand



Related links


Revista Uruguaya de Cardiología

Print version ISSN 0797-0048On-line version ISSN 1688-0420


GOMEZ, Andreina et al. Usefulness of the SAMe-TT2R2 score in the control of oral anticoagulation with warfarin in patients with non-valvular atrial fibrillation. Rev.Urug.Cardiol. [online]. 2016, vol.31, n.3, pp.381-389. ISSN 0797-0048.

Background: prevention of thromboembolic events is the main objective of oral anticoagulation treatment in non-valvular atrial fibrillation (AF) and either oral anticoagulation with vitamin K antagonists (VKA), like warfarin, or direct oral anticoagulants (ACOD) can be used. When warfarin is used, a time in therapeutic range (TTR) >65- 70% offers the best efficacy and safety. The SAMe-TT2R2 score has been developed as a tool to predict the response to VKA. A favorable SAMe-TT2R2 score (0-1 point) can identify patients that respond adequately to VKA and will have a better TTR, whilst a not favorable SAMe-TT2R2score (2 points) associates with poor TTR, needing additional therapies to optimize anticoagulation quality control or would be better candidates to direct oral anticoagulants (ACOD) Objective: assess SAMe-TT2R2 score value in anticoagulation quality control of patients with non-valvular AF treated with warfarin. Method: retrospective study of 115 ambulatory patients with non-valvular AF receiving oral anticoagulation treatment with warfarin, from June 1st 2012 to June 31st 2014. Analyzed variables were age, sex, left ventricle ejection fraction (LVEF), comorbidities, number of concomitant drugs, CHA2DS2-VASc and HAS-BLED scores. Rosendaal method was used to calculate the individual TTR. Student T test was used to compare mean values and X2 test for categorical variables. P < 0.05 was considered statistically significant. Results: mean age was 71.0 ± 9.8 years, 52.2% were male, most frequent comorbidities were: hypertension 82.6%, ischemic heart disease 24.3%, diabetes mellitus 18.3%, cerebrovascular disease 10.4%, smoking 6.1% and former smoking 30.4%, concomitant use of 3 or more drugs 87%. Mean LVEF was 48.3 ± 12.5 %, CHA2DS2-VASc Score 3.6 ± 1.2 points and HAS-BLED Score 1.8 ± 0.9 points. Mean TTR was 54.9 ± 21.6% and only 37 patients (32.2%) had a TTR  65%. Mean SAMe-TT2R2 score was 1.8 ± 1.0 points, a warfarin-favorable score (0-1 point) was found in 45 patients (39.1%) and 70 patients (60.9%) had a non-favorable score (2 points). No significant mean TTR difference was found among SAMe-TT2R2 categories (53.0 ± 23.7% vs. 56.2 ± 20.2%, p=0.447). No association between a favorable SAMe-TT2R2 Score and a high TTR (65%) was found (33.3 vs. 31.4%, p=0.831). Conclusion: no difference in anticoagulation quality control was found among favorable and non-favorable SAMe-TT2R2 score categories.

Keywords : ATRIAL FIBRILLATION; WARFARIN; ANTICOAGULANTS; VITAMIN K; therapeutic use; VITAMIN K; antagonists & inhibitors; SAMe-TT2R2.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License